RA Capital Management’s Celldex Therapeutics CLDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-1,734,972
| Closed | -$62.4M | – | 55 |
|
|
2023
Q1 | $62.4M | Sell |
1,734,972
-340,028
| -16% | -$12.2M | 1.41% | 24 |
|
|
2022
Q4 | $92.5M | Hold |
2,075,000
| – | – | 1.88% | 20 |
|
|
2022
Q3 | $58.3M | Hold |
2,075,000
| – | – | 1.24% | 29 |
|
|
2022
Q2 | $55.9M | Hold |
2,075,000
| – | – | 1.49% | 19 |
|
|
2022
Q1 | $70.7M | Buy |
2,075,000
+270,205
| +15% | +$9.2M | 1.54% | 16 |
|
|
2021
Q4 | $69.7M | Buy |
1,804,795
+204,795
| +13% | +$7.91M | 1.23% | 21 |
|
|
2021
Q3 | $86.4M | Buy |
+1,600,000
| New | +$86.4M | 1.2% | 27 |
|
|
2020
Q4 | – | Sell |
-353,072
| Closed | -$5.24M | – | 83 |
|
|
2020
Q3 | $5.24M | Sell |
353,072
-796,928
| -69% | -$11.8M | 0.1% | 65 |
|
|
2020
Q2 | $15M | Buy |
+1,150,000
| New | +$15M | 0.29% | 45 |
|